Bullfrog AI (NASDAQ:BFRG) versus ANGLE (OTCMKTS:ANPCY) Financial Comparison

ANGLE (OTCMKTS:ANPCY) and Bullfrog AI (NASDAQ:BFRG) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.

Institutional & Insider Ownership

1.0% of Bullfrog AI shares are owned by institutional investors. 14.7% of Bullfrog AI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for ANGLE and Bullfrog AI, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANGLE	0	0	0	0	0.00
Bullfrog AI	1	1	0	0	1.50

Earnings and Valuation

This table compares ANGLE and Bullfrog AI”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANGLE	N/A	N/A	N/A	C($0.48)	-0.14
Bullfrog AI	$120,000.00	85.75	-$6.50 million	($0.54)	-1.03

ANGLE has higher earnings, but lower revenue than Bullfrog AI. Bullfrog AI is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ANGLE and Bullfrog AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ANGLE	N/A	N/A	N/A
Bullfrog AI	N/A	-217.80%	-174.57%

About ANGLE

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.